Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers
It is believed that pathways of the immune system are responsible for eradicating cancer cells; however, their over-activation and also their ectopic expression in tumor cells and microenvironment are major contributors to tumor growth and chemoresistance. Toll-like receptor 4 (TLR4) pathway is an innate immune-related pathway which is usually overexpressed in tumor cells that leads to excessive pro-inflammatory cytokines and eventually results in tumor survival, drug resistance, and metastasis. In this study, we investigated whether TLR4 expression is affected upon the treatment of breast and ovarian cancer cells with common chemotherapeutics (paclitaxel, cisplatin, doxorubicin, and arsenic trioxide) and if TLR4 inhibition using its specific inhibitor TAK-242 could enhance cancer cells’ response to the drugs. Both breast (MCF7) and ovarian (2008C13) cancer cells experienced an elevated expression of TLR4 after treatment with the drugs. The expression of this receptor was also upregulated in cisplatin-resistant 2008C13 cells; however, it was significantly higher upon short-term treatment with cisplatin. More importantly, the combination treatment of the drugs with TAK-242 intensified the chemosensitivity of six different breast and ovarian cancer cells to chemotherapeutic drugs. It was also identified that co-treatment of paclitaxel and TAK-242 not only led to enhanced G2/M arrest and apoptosis but also satisfactorily decreased the expression of TLR4 and different interleukins in these cells. Taken together, the results of the present study emphasize that chemotherapy may lead to chemoresistance through inducing TLR4 expression, and therefore inhibiting this receptor using TAK-242 could be a promising approach to improve the outcome of chemotherapy in foreseeable future.
KeywordsToll-like receptor 4 (TLR4) TAK-242 Chemotherapy Combination therapy Breast and ovarian cancers
The authors would like to acknowledge the help provided by the Medical University of Bam.
Research reported in this publication was supported by a grant from Hematology, Oncology, and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving human participants and/or animals
- 1.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.Google Scholar
- 2.Doubeni CA, Doubeni AR, Myers AE, Doubeni AR. Diagnosis and Management of Ovarian Cancer. American family physician. 2016 Jun 1;93(11).Google Scholar
- 7.Moscow JA, Cowan KH, Sikic BI. Drug resistance and its clinical circumvention. Holland‐Frei Cancer Medicine. 2016 Oct 17:1-7.Google Scholar
- 22.Okada T, Lei L, Nishikawa H, Nakano F, Nakatsuka Y, Suzuki H. TAK-242, toll-like receptor 4 antagonist, attenuates brain edema in subarachnoid hemorrhage mice. Subarachnoid Hemorrhage: Springer; 2020. p. 77–81.Google Scholar
- 23.Zandi Z, Kashani B, Bashash D, Poursani EM, Mousavi SA, Chahardoli B, Ghaffari SH. The anticancer effect of the TLR4 inhibition using TAK‐242 (resatorvid) either as a single agent or in combination with chemotherapy: A novel therapeutic potential for breast cancer. Journal of cellular biochemistry. 2019 Sep 18.Google Scholar
- 24.Kashani B, Zandi Z, Bashash D, Zaghal A, Momeny M, Poursani EM, Pourbagheri-Sigaroodi A, Mousavi SA, Ghaffari SH. Small molecule inhibitor of TLR4 inhibits ovarian cancer cell proliferation: new insight into the anticancer effect of TAK-242 (Resatorvid). Cancer Chemotherapy and Pharmacology. 2019 Nov 30:1-3.Google Scholar
- 25.Zandi Z, Kashani B, Poursani EM, Bashash D, Kabuli M, Momeny M, et al. TLR4 blockade using TAK-242 suppresses ovarian and breast cancer cells invasion through the inhibition of extracellular matrix degradation and epithelial-mesenchymal transition. Eur J Pharmacol. 2019;853:256–63. https://doi.org/10.1016/j.ejphar.2019.03.046.CrossRefPubMedGoogle Scholar
- 26.Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010:0008–5472. CAN-09-1947.Google Scholar
- 38.Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A, et al. Triggering of toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res. 2009;69(7):3105–13.PubMedPubMedCentralGoogle Scholar
- 44.Zhou S, Du R, Wang Z, Shen W, Gao R, Jiang S, Fang Y, Shi Y, Chang A, Liu L, Liu C. TLR 4 increases the stemness and is highly expressed in relapsed human hepatocellular carcinoma. Cancer medicine. 2019 May 1.Google Scholar
- 45.Rothchild, Greg A., George Sandusky, Constance J. Temm, and Costantine Albany. "Identifying a predictive biomarker for chemotherapy (taxane) in patients with metastatic castration resistance prostate cancer." (2016): 426-426.Google Scholar
- 47.Wang A, Su Q, Wu F, Zhang X, Liu P. Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells. Eur J Clin Investig. 2009;39(2):157–64.Google Scholar